Lead Product(s) : RP-001,Inapplicable
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : TVM Capital Life Science
Deal Size : $24.0 million
Deal Type : Financing
Details : Recurv Pharma will use the funding in the development of a novel taxane therapy, RP-001, therapy to treat solid tumors. RP-001 is a new chemical entity (NCE) delivered in a nano-emulsion formulation that focuses the drug delivery to the tumor, sparing he...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 02, 2023
Lead Product(s) : RP-001,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : TVM Capital Life Science
Deal Size : $24.0 million
Deal Type : Financing
Reset All
